Skip to main content
. 2022 Jul 30;14(15):3726. doi: 10.3390/cancers14153726

Figure 4.

Figure 4

Dasatinib synergises with CDDP in OAC cell lines: (a) OAC cells were treated with ~IC30(72 h) doses of dasatinib/CDDP for 72 h and viability was assessed by MTT. The results represent the mean ± SEM of triplicate experiments. (b) Drug interactions were then assessed following 72 h dasatinib/CDDP combinations (≤~IC30(72 h)) by combination index (CI), where a CI < 1 indicates synergy, CI = 1 indicates additive, and CI > 1 indicates an antagonistic interaction. (c) Western blot analysis of PARP in OE33 FLO-1 and MFD-1 cells following 72 h ~IC30(72 h) dasatinib/CDDP combinations with vinculin as a loading control. (d) Propidium iodide flow cytometry of Sub-G1 phase following 72 h ~IC30(72 h) CDDP/dasatinib combination. (e) Proliferation rates at 24, 48, and 72 h post combination treatment. The results represent the mean ± SEM of triplicate experiments. Significance was assessed using Student’s t-test (* p < 0.05, ** p < 0.01, *** p < 0.001). CON, control; NS, not significant.